Differential (Click to cross reference) advances in neurology calcitonin gene related peptide calcitonin gene-related peptide receptor blocker cerebrovascular accident cerebrovascular accident, acute management of cerebrovascular accident, age of lesion cerebrovascular accident, awakening with cerebrovascular accident, thrombolytic agents in treatment cerebrovascular accident, time of onset cerebrovascular accident, time to treatment cerebrovascular accident, unknown time of onset complications efficacy erenumab fibrinolytic agents fibrinolytic therapy, selection criteria fibrinolytic therapy, timing of administration fremanezumab galcanezumab headache intracerebral hemorrhage migraine migraine, chronic migraine, prophylaxis migraine, treatment of monoclonal antibodies MR WITNESS trial MRI MRI, abnormal MRI, diffusion weighted MRI, mismatch between DWI/FLAIR patient selection prevention of neurologic disorders quality of life review article safety tissue plasminogen activator, intravenous treatment of neurologic disorder

Showing articles 0 to 5 of 5 Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019 Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019 Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018 Preventive Migraine Drug Approved JAMA 320:1746, , 2018 CGRP - The Next Frontier for Migraine NEJM 377:2190-2191, Hershey, A.D., 2017 Showing articles 0 to 5 of 5